221 related articles for article (PubMed ID: 30341138)
1. What is associated with increased side effects and lower perceived efficacy following switching to a generic medicine? A New Zealand cross-sectional patient survey.
MacKrill K; Petrie KJ
BMJ Open; 2018 Oct; 8(10):e023667. PubMed ID: 30341138
[TBL] [Abstract][Full Text] [Related]
2. The effect of generic switching on concerns about medicine and non-persistence among Danish adults in a general practice setting.
Rathe JØ
Dan Med J; 2015 Oct; 62(10):B5148. PubMed ID: 26441397
[TBL] [Abstract][Full Text] [Related]
3. Changing perceptions and efficacy of generic medicines: An intervention study.
Colgan SL; Faasse K; Pereira JA; Grey A; Petrie KJ
Health Psychol; 2016 Nov; 35(11):1246-1253. PubMed ID: 27505191
[TBL] [Abstract][Full Text] [Related]
4. The effect of an apparent change to a branded or generic medication on drug effectiveness and side effects.
Faasse K; Cundy T; Gamble G; Petrie KJ
Psychosom Med; 2013 Jan; 75(1):90-6. PubMed ID: 23115341
[TBL] [Abstract][Full Text] [Related]
5. Patients' concern about their medicine after a generic switch: a combined cross-sectional questionnaire and register study.
Rathe J; Søndergaard J; Jarbøl DE; Hallas J; Andersen M
Pharmacoepidemiol Drug Saf; 2014 Sep; 23(9):965-73. PubMed ID: 24946275
[TBL] [Abstract][Full Text] [Related]
6. Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study.
Desai RJ; Sarpatwari A; Dejene S; Khan NF; Lii J; Rogers JR; Dutcher SK; Raofi S; Bohn J; Connolly J; Fischer MA; Kesselheim AS; Gagne JJ
BMJ; 2018 Apr; 361():k1180. PubMed ID: 29615391
[TBL] [Abstract][Full Text] [Related]
7. Perceptions and behaviors of patients and pharmacists towards generic drug substitution in Lebanon.
Saleh S; Abou Samra C; Jleilaty S; Constantin J; El Arnaout N; Dimassi H; Al-Bittar D
Int J Clin Pharm; 2017 Oct; 39(5):1101-1109. PubMed ID: 28823020
[TBL] [Abstract][Full Text] [Related]
8. Predictors of statin compliance after switching from branded to generic agents among managed-care beneficiaries.
Romanelli RJ; Segal JB
J Gen Intern Med; 2014 Oct; 29(10):1372-8. PubMed ID: 24957381
[TBL] [Abstract][Full Text] [Related]
9. Associations between generic substitution and patients' attitudes, beliefs and experiences.
Rathe J; Larsen P; Andersen M; Paulsen M; Jarbøl D; Thomsen J; Soendergaard J
Eur J Clin Pharmacol; 2013 Oct; 69(10):1827-36. PubMed ID: 23765409
[TBL] [Abstract][Full Text] [Related]
10. An Evaluation of Health Service Impacts Consequent to Switching from Brand to Generic Venlafaxine in New Zealand under Conditions of Price Neutrality.
Lessing C; Ashton T; Davis P
Value Health; 2015 Jul; 18(5):646-54. PubMed ID: 26297093
[TBL] [Abstract][Full Text] [Related]
11. Cost sharing and branded antidepressant initiation among patients treated with generics.
Buxbaum JD; Chernew ME; Bonafede M; Vlahiotis A; Walter D; Mucha L; Fendrick AM
Am J Manag Care; 2018 Apr; 24(4):180-186. PubMed ID: 29668208
[TBL] [Abstract][Full Text] [Related]
12. The Power of Labeling in Nocebo Effects.
Faasse K; Martin LR
Int Rev Neurobiol; 2018; 139():379-406. PubMed ID: 30146055
[TBL] [Abstract][Full Text] [Related]
13. Patients' beliefs and behaviours are associated with perceptions of safety and concerns in a hypothetical biosimilar switch.
Gasteiger C; Lobo M; Dalbeth N; Petrie KJ
Rheumatol Int; 2021 Jan; 41(1):163-171. PubMed ID: 32300866
[TBL] [Abstract][Full Text] [Related]
14. Branded versus generic drug use in chronic disease management in Hong Kong-perspectives of health care professionals and the general public.
Lee VW; Cheng FW; Fong FY; Ng EE; Lo LL; Ngai LY; Lam AS
Hong Kong Med J; 2018 Dec; 24(6):554-560. PubMed ID: 30530869
[TBL] [Abstract][Full Text] [Related]
15. Generic switching and non-persistence among medicine users: a combined population-based questionnaire and register study.
Rathe J; Andersen M; Jarbøl DE; dePont Christensen R; Hallas J; Søndergaard J
PLoS One; 2015; 10(3):e0119688. PubMed ID: 25775472
[TBL] [Abstract][Full Text] [Related]
16. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.
Andermann F; Duh MS; Gosselin A; Paradis PE
Epilepsia; 2007 Mar; 48(3):464-9. PubMed ID: 17346246
[TBL] [Abstract][Full Text] [Related]
17. Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy.
Makus KG; McCormick J
Clin Ther; 2007 Feb; 29(2):334-41. PubMed ID: 17472825
[TBL] [Abstract][Full Text] [Related]
18. Generic and therapeutic statin switches and disruptions in therapy.
Chapman RH; Benner JS; Girase P; Benigno M; Axelsen K; Liu LZ; Nichol MB
Curr Med Res Opin; 2009 May; 25(5):1247-60. PubMed ID: 19344292
[TBL] [Abstract][Full Text] [Related]
19. Impact of brand or generic labeling on medication effectiveness and side effects.
Faasse K; Martin LR; Grey A; Gamble G; Petrie KJ
Health Psychol; 2016 Feb; 35(2):187-90. PubMed ID: 26462056
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Switch-to-Brand Rates as a Potential Signal for Therapeutic Equivalency of Generic Antidepressants: A Real-World Retrospective Cohort Study.
Kalaria S; Spence O; Hong K; dosReis S; Gopalakrishnan M
Clin Pharmacol Ther; 2021 Aug; 110(2):443-451. PubMed ID: 33811324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
